Vascular targeted therapies in oncology
- 28 August 2008
- journal article
- review article
- Published by Springer Science and Business Media LLC in Cell and tissue research
- Vol. 335 (1), 241-248
- https://doi.org/10.1007/s00441-008-0646-0
Abstract
Neovascularization is intimately involved in tumor survival, progression, and spread, factors known to contribute significantly to treatment failures. Thus, strategies targeting the tumor blood vessel support network may offer not only unique therapeutic opportunities in their own right, but also novel means of enhancing the efficacies of conventional anticancer treatments. This article reviews one such therapeutic approach directed at the tumor blood vessel support network. Vascular disrupting therapies seek the destruction of the established neovasculature of actively growing tumors. The goal of these therapies is to cause a rapid and catastrophic shutdown in the vascular function of the tumor in order to arrest the blood flow and produce tumor cell death as a result of oxygen and nutrient deprivation and the build up of waste products.Keywords
This publication has 44 references indexed in Scilit:
- An update on the clinical development of drugs to disable tumor vasculatureExpert Opinion on Drug Discovery, 2007
- On the Origin and Nature of Elevated Levels of Circulating Endothelial Cells After Treatment With a Vascular Disrupting AgentJournal of Clinical Oncology, 2006
- Effect of the Second-Generation Vascular Disrupting Agent OXi4503 on Tumor VascularityClinical Cancer Research, 2006
- 5,6-Dimethylxanthenone-4-Acetic Acid in the Treatment of Refractory Tumors: a Phase I Safety Study of a Vascular Disrupting AgentClinical Cancer Research, 2006
- Combretastatin A4 phosphate induces rapid regression of tumor neovessels and growth through interference with vascular endothelial-cadherin signalingJCI Insight, 2005
- Role of angiogenesis in tumor growth and metastasisSeminars in Oncology, 2002
- Specialization of tumour vasculatureNature Reviews Cancer, 2002
- Overview of angiogenesis: Biologic implications for antiangiogenic therapySeminars in Oncology, 2001
- Vascular Endothelial Growth Factor in Human Colon Cancer: Biology and Therapeutic ImplicationsThe Oncologist, 2000
- New strategies in anti‐vascular cancer therapyEuropean Journal of Clinical Investigation, 1999